Johnson  Johnson Acquires Ollin Biosciences, Funds Phase 3 Program with Blackstone Capital
Trendline

Johnson Johnson Acquires Ollin Biosciences, Funds Phase 3 Program with Blackstone Capital

What's Happening? Johnson & Johnson (J&J) has announced the acquisition of Ollin Biosciences for $2.2 billion upfront, with additional regulatory milestone payments. This acquisition brings OLN324, a VEGF/Ang2 bispecific antibody for wet Age-related Macular Degeneration (AMD) and Diabetic Macular Ed
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.